Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2 contributes to human bladder cancer cell survival

BMC Urology

Volumn 11, Issue , 2011, Pages

  Shimada, Keiji ^a   Anai, Satoshi ^a   Marco, Develasco A ^b   Fujimoto, Kiyohide ^a   Konishi, Noboru ^a  

^a NARA MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Akt; casein kinase 2 ? ?; cyclooxygenase 2; urothelial carcinoma

Indexed keywords

ATELOCOLLAGEN; CASEIN KINASE 2ALPHA; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MELOXICAM; PROTEIN KINASE B; PROTEIN P27; PROTEIN SERINE THREONINE KINASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UROKINASE; CASEIN KINASE II; ONCOPROTEIN;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CANCER SURVIVAL; CARCINOMA IN SITU; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INVASIVE CARCINOMA; ORTHOTOPIC TRANSPLANTATION; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; UPREGULATION; ANIMAL; BLADDER TUMOR; CELL SURVIVAL; METABOLISM; MOUSE; TUMOR CELL LINE;

ANIMALS; CASEIN KINASE II; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOOXYGENASE 2; HUMANS; MICE; ONCOGENE PROTEIN V-AKT; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 79955952869     PISSN: 14712490     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-11-8     Document Type: Article

References (30)

1. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. A Greenhough HJ Smartt AE Moore HR Roberts AC Williams C Paraskeva A Kaidi, Carcinogenesis 2009 30 377 386 10.1093/carcin/bgp014 19136477
2. Role of cyclooxygenase-2 in colorectal cancer. FA Sinicrope S Gill, Cancer Metastasis Rev 2004 23 63 75 15000150 (Pubitemid 38221596)
3. Cancer genes and the pathways they control. B Vogelstein KW Kinzler, Nat Med 2004 10 789 799 10.1038/nm1087 15286780 (Pubitemid 39070849)
4. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. M Tsujii RN DuBois, Cell 1995 83 493 501 10.1016/0092-8674(95)90127-2 8521479
5. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: implications for the possible role of dietary fibre in the prevention of large-bowel cancer. A Hague AM Manning KA Hanlon LI Huschtscha D Hart C Paraskeva, Int J Cancer 1993 55 498 505 10.1002/ijc. 2910550329 8397167 (Pubitemid 23300605)
6. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. CH Liu SH Chang K Narko OC Trifan MT Wu E Smith C Haudenschild TF Lane T Hla, J Biol Chem 2001 276 18563 18569 10.1074/jbc.M010787200 11278747
7. Transgenic expression of cyclooxygenase-2 in mouse intestine epithelium is insufficient to initiate tumorigenesis but promotes tumor progression. MA Al-Salihi A Terrece Pearman T Doan EC Reichert DW Rosenberg SM Prescott DM Stafforini MK Topham, Cancer Lett 2009 273 225 232 10.1016/j.canlet.2008.08.012 18790560
8. Strategies for molecular expression profiling in bladder cancer. AP Mitra CC Bartsch RJ Cote, Cancer Metastasis Rev 2009 28 317 326 10.1007/s10555-009- 9196-5 19997771
9. Cyclooxygenase-2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. P Wadhwa AK Goswami K Joshi SK Sharma, Int Urol Nephrol 2005 37 47 53 10.1007/s11255-004-4699-z 16132759 (Pubitemid 41236242)
10. Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder. S Gurocak S Sozen O Erdem S Ozkan Y Kordan T Alkibay G Akyol I Bozkirli, Urol Int 2006 76 51 56 10.1159/000089735 16401921 (Pubitemid 43087521)
11. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. J Gee IL Lee D Jendiroba SM Fischer HB Grossman AL Sabichi, Oncol Rep 2006 15 471 477 16391871
12. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology. JH Trembley G Wang G Unger J Slaton K Ahmed, Cell Mol Life Sci 2009 66 1858 1867 10.1007/s00018-009-9154-y 19387548
13. Protein kinase CK2: a challenge to canons. LA Pinna, J Cell Sci 2002 115 3873 3878 10.1242/jcs.00074 12244125 (Pubitemid 35256488)
14. Protein kinase CK2 signal in neoplasia. S Tawfic S Yu H Wang R Faust A Davis K Ahmed, Histol Histopathol 2001 16 573 582 11332713 (Pubitemid 32297655)
15. Protein kinase CK2 and its role in cellular proliferation, development and pathology. B Guerra OG Issinger, Electrophoresis 1999 20 391 408 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS3913.0.CO;2-N 10197447 (Pubitemid 29125027)
16. Response of cancer cells to molecular interruption of the CK2 signal. H Wang A Davis S Yu K Ahmed, Mol Cell Biochem 2001 227 167 174 10.1023/A:1013112908734 11827168 (Pubitemid 34048381)
17. Characterization of a panel of cell lines derived from urothelial neoplasms: genetic alterations, growth in vivo and the relationship of adenoviral mediated gene transfer to coxsackie adenovirus receptor expression. A Sabichi A Keyhani N Tanaka J Delacerda IL Lee C Zou JH Zhou WF Benedict HB Grossman, J Urol 2006 175 1133 1137 10.1016/S0022-5347(05)00323-X 16469639 (Pubitemid 43200116)
18. [Studies on KU-1 and KU-7 cells as an in vitro model of human transitional cell carcinoma of urinary bladder]. H Tazaki M Tachibana, Hum Cell 1988 1 78 83 3154018
19. A novel human AlkB homologue, ALKBH8, contributes to human bladder cancer progression. K Shimada M Nakamura S Anai M De Velasco M Tanaka K Tsujikawa Y Ouji N Konishi, Cancer Res 2009 69 3157 3164 19293182
20. Visualizing superficial human bladder cancer cell growth in vivo by green fluorescent protein expression. JH Zhou CJ Rosser M Tanaka M Yang E Baranov RM Hoffman WF Benedict, Cancer Gene Ther 2002 9 681 686 10.1038/sj.cgt.7700489 12136429 (Pubitemid 34847576)
21. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression. K Shimada S Matsuyoshi M Nakamura E Ishida N Konishi, J Pathol 2005 206 423 432 10.1002/path.1791 15906275 (Pubitemid 41025345)
22. c-Jun NH2 terminal kinase activation and decreased expression of mitogen-activated protein kinase phosphatase-1 play important roles in invasion and angiogenesis of urothelial carcinomas. K Shimada M Nakamura E Ishida T Higuchi M Tanaka I Ota N Konishi, Am J Pathol 2007 171 1003 1012 10.2353/ajpath.2007.070010 17690186 (Pubitemid 47440997)
23. Heterogeneous methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. N Konishi M Nakamura M Kishi M Nishimine E Ishida K Shimada, Am J Pathol 2002 160 1207 1214 10.1016/S0002-9440(10)62547-3 11943705 (Pubitemid 34411624)
24. Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues. PN Span JA Witjes N Grebenchtchikov A Geurts-Moespot PM Moonen TW Aalders JL Vriesema LA Kiemeney JA Schalken FC Sweep, BJU Int 2008 102 177 182 10.1111/j.1464-410X.2008.07568.x 18336603 (Pubitemid 351852589)
25. Inhibition of RelA phosphorylation sensitizes apoptosis in constitutive NF-kappaB-expressing and chemoresistant cells. SK Manna P Manna A Sarkar, Cell Death Differ 2007 14 158 170 10.1038/sj.cdd.4401929 16645640 (Pubitemid 44911903)
26. Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells. G Di Maira F Brustolon LA Pinna M Ruzzene, Cell Mol Life Sci 2009 66 3363 3373 10.1007/s00018-009-0108-1 19662498
27. Modulation of Akt kinase activity by binding to Hsp90. S Sato N Fujita T Tsuruo, Proc Natl Acad Sci USA 2000 97 10832 10837 10995457
28. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. MA Knowles FM Platt RL Ross CD Hurst, Cancer Metastasis Rev 2009 28 305 316 10.1007/s10555-009-9198-3 20013032
29. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. H Tsuruta H Kishimoto T Sasaki Y Horie M Natsui Y Shibata K Hamada N Yajima K Kawahara M Sasaki N Tsuchiya K Enomoto W MAkt T Nakano T Habuchi A Suzuki, Cancer Res 2006 66 8389 8396 10.1158/0008-5472.CAN-05-4627 16951148 (Pubitemid 44449149)
30. Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. M Chen A Cassidy J Gu GL Delclos F Zhen H Yang MA Hildebrandt J Lin Y Ye RM Chamberlain CP Dinney X Wu, Carcinogenesis 2009 30 2047 2052 10.1093/carcin/bgp258 19875696